Antimuscarinics and the overactive detrusor--which is the main mechanism of action?
about
Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions.Trospium chloride treatment of overactive bladderAltered detrusor contractility in MPTP-treated common marmosets with bladder hyperreflexia.Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)Origin of spontaneous activity in neonatal and adult rat bladders and its enhancement by stretch and muscarinic agonistsMuscarinic receptors in the bladder: from basic research to therapeutics.The effect of indomethacin on the muscarinic induced contractions in the isolated normal guinea pig urinary bladder.Non-neuronal acetylcholine and urinary bladder urothelium.Muscarinic regulation of neonatal rat bladder spontaneous contractions.Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing.Pharmacodynamics of propiverine and three of its main metabolites on detrusor contractionRole of Nicotinic Acetylcholine Receptor α3 and α7 Subunits in Detrusor Overactivity Induced by Partial Bladder Outlet Obstruction in Rats.Dissimilar effects of tolterodine on detrusor overactivity in awake rats with chemical cystitis and partial bladder outlet obstruction.Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladderInterstitial cystitis and frequency-urgency syndrome (OAB syndrome).Role of serotonin and noradrenaline in stress urinary incontinence.A developing view of the origins of urgency: the importance of animal models.More than just a barrier: urothelium as a drug target for urinary bladder pain.A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder.Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?Long-term safety, efficacy, and tolerability of imidafenacin in the treatment of overactive bladder: a review of the Japanese literature.Transdermal drug delivery treatment for overactive bladder.Tolterodine for the treatment of overactive bladder.In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder.Role of fesoterodine in the treatment of overactive bladder.Oxybutynin topical gel in the treatment of overactive bladderUpdate on the management of overactive bladder: patient considerations and adherenceTolterodine extended release is well tolerated in older subjectsExpression of functional nicotinic acetylcholine receptors in rat urinary bladder epithelial cells.Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.Fesoterodine for the treatment of urinary incontinence and overactive bladder.Purinergic and muscarinic modulation of ATP release from the urothelium and its paracrine actions.Fesoterodine for the treatment of overactive bladder.Rationale for the use of prostaglandins and phosphodiesterase inhibitors in the treatment of functional bladder disorders.Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.Combination of foot stimulation and tolterodine treatment eliminates bladder overactivity in cats.The medical treatment of overactive bladder, including current and future treatments.The etiology and management of acute prostatitis.Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.
P2860
Q24812265-5E4F0230-B445-45D0-A5D4-87D740CB174BQ28308162-7143DACE-4788-4F2A-8DBE-70BE609EEFDDQ33698838-1E2C6E81-EAA2-4194-9BB1-8AEF4C446C4BQ33835874-D8037D2C-DFFB-4875-B25A-5184638E1438Q34548809-4F5CDD83-7D24-4F8D-9F4D-9D849E94CF06Q34564708-3BDC4143-7A9E-43EE-B168-8BD30767632AQ34578718-F90C917B-030C-47FB-B7EE-54CFCEFFE656Q34903817-0D8CC4A6-6235-4635-AE53-B39FB20D0CDBQ35037138-E031F06C-4911-4C11-A2DE-AD80D94682CAQ35048803-9DCA0648-0988-4C0E-8E28-A33138784A44Q35048983-2BA633B1-3AB8-4687-8C01-895398172F16Q35281118-49B2A2A8-0A53-4E5B-BD9B-24713ABB3A36Q35539606-8FBD8669-8E44-4078-ABE8-0BB6859C49EDQ35546189-9E442F2E-BCF6-4F58-8012-2C5E8EFE1420Q35594530-32833063-1AA5-44B1-9830-A91DD564EBFCQ35771624-42FCDF9D-4A98-49A9-BA9D-25CE7195240BQ36222101-8C67BEC8-A345-4EB1-AA88-426CE3D493E3Q36225080-5BCF0762-7BA6-477D-83DB-29A25146F431Q36573702-39A9AFDF-7466-412D-90E3-5399A1DBCD8CQ36574048-9A1A298B-ABF7-42CD-9D2D-DD1854139781Q36587687-4515EBAB-B062-45F8-9018-D0886557BF96Q36642882-3D1CC3E3-F8C4-44A2-AAA3-C719424FEF6BQ37142090-0EB3BFE5-32C2-4613-9637-23EA4FAD981EQ37230811-7777A7E7-8147-4C07-9935-9B4E9C6D3D01Q37283542-33B234BA-EE5C-445F-89BE-0EECDD142813Q37283566-09016DF4-D894-4876-A958-3ED2993E4E1EQ37283704-465DE889-B6D7-43E1-9EB2-632C64451705Q37332901-36FDBE6E-BDCC-4396-B120-9B40079D2479Q37383360-D7494C2E-0BCB-4A66-8927-F29DF8169A08Q37405499-845B5611-9F39-489A-AD1B-432BA828384DQ37429813-104846FB-4E7C-4980-B2EC-7D0E1F9014BCQ37575585-FE2BF1CB-C481-4430-9495-2D931C61722DQ37634191-DF869D4B-9732-455C-A93C-EAAEDD28107DQ37639128-37D3528E-FCE4-43D6-AE7B-1CCB16D74B78Q37642772-00C9BBC3-BB3C-4BA8-9818-56E6A833176FQ37687465-0E5C8AB6-1DDE-48EA-81CC-E639B4DBFF83Q37728633-3228CD99-DEA5-4246-8A05-6CB0E7119C96Q37836943-8BC741E7-D924-4881-A54B-F9DC16D71581Q37853019-AD11D0B8-01C9-4FAF-8D46-42B91E76C95EQ37879017-3B7DFD60-668E-492E-8998-DB255FC4A51F
P2860
Antimuscarinics and the overactive detrusor--which is the main mechanism of action?
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Antimuscarinics and the overactive detrusor--which is the main mechanism of action?
@ast
Antimuscarinics and the overactive detrusor--which is the main mechanism of action?
@en
type
label
Antimuscarinics and the overactive detrusor--which is the main mechanism of action?
@ast
Antimuscarinics and the overactive detrusor--which is the main mechanism of action?
@en
prefLabel
Antimuscarinics and the overactive detrusor--which is the main mechanism of action?
@ast
Antimuscarinics and the overactive detrusor--which is the main mechanism of action?
@en
P1433
P1476
Antimuscarinics and the overactive detrusor--which is the main mechanism of action?
@en
P2093
Andersson KE
P356
10.1016/S0302-2838(02)00540-7
P407
P577
2003-01-01T00:00:00Z